Advances in Cell-Based Technologies for Precision Diagnostics

A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Clinical Laboratory Medicine".

Deadline for manuscript submissions: 30 November 2024 | Viewed by 5409

Special Issue Editors


E-Mail Website
Guest Editor
Sysmex Asia Pacific Pte Ltd., Singapore 528735, Singapore
Interests: laboratory medicine; cell-based diagnosis

E-Mail Website
Guest Editor
1. Institute for Health Innovation & Technology (iHealthtech), National University of Singapore (NUS), MD6, 14 Medical Drive, #14-01, Singapore 117599, Singapore
2. Department of Biomedical Engineering, National University of Singapore (NUS), 4 Engineering Drive 3, Singapore 117583, Singapore
Interests: wearable soft microtube sensors; cell-based diagnosis
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

In the dynamic landscape of laboratory medicine, where approximately 70% of all medical decisions are grounded in laboratory results, the pivotal role of cell-based diagnostics has been increasingly recognized as a transformative force. This call for contributions stems from the profound impact witnessed across diverse domains within the realm of general laboratory medicine.

Cell-based diagnostics extend beyond specific disciplines to encompass infectious diseases, oncology, tropical diseases, and an array of non-malignant conditions. Similar to the progress that has been made in preventing the manifestation of inherited genetic disorders, advancements in cell-based diagnostics empower early intervention, preventive strategies, and personalized treatments tailored to individual patient profiles. Much like the convergence that has been observed across various medical specialties, experts in cell-based diagnostics bridge the realms of clinical care and laboratory precision. The sophistication of cell-based technologies demands a comprehensive understanding of both the clinical context and laboratory intricacies. This intersection holds the key to redefining diagnostic paradigms and significantly impacting patient outcomes across diverse medical fields.

This Special Issue aims to spotlight recent developments in cell-based technologies and their pivotal role in shaping the landscape of precision diagnostics. We invite contributions focusing on current laboratory analytical performance and research related to biomedical applications. Additionally, we welcome submissions spanning fundamental cellular analyses, innovative applications of flow cytometry, breakthroughs in immunohistochemistry, and insights from cytogenetic studies. Our goal is to offer an insightful panorama of the dynamic landscape of cell-based diagnostics, highlighting their significance within the realm of general laboratory medicine.

Dr. Swee Jin Tan
Dr. Ali Asgar Bhagat
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cell-based technology
  • laboratory medicine
  • precision diagnostics
  • cellular analysis
  • flow cytometry
  • immunohistochemistry
  • cytogenetic study

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (3 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

12 pages, 2456 KiB  
Article
Spheroids Generated from Malignant Pleural Effusion as a Tool to Predict the Response of Non-Small Cell Lung Cancer to Treatment
by Tsung-Ming Yang, Yu-Hung Fang, Chieh-Mo Lin, Miao-Fen Chen and Chun-Liang Lin
Diagnostics 2024, 14(10), 998; https://doi.org/10.3390/diagnostics14100998 - 11 May 2024
Cited by 1 | Viewed by 1325
Abstract
Background: Spheroids generated by tumor cells collected from malignant pleural effusion (MPE) were shown to retain the characteristics of the original tumors. This ex vivo model might be used to predict the response of non-small cell lung cancer (NSCLC) to anticancer treatments. Methods: [...] Read more.
Background: Spheroids generated by tumor cells collected from malignant pleural effusion (MPE) were shown to retain the characteristics of the original tumors. This ex vivo model might be used to predict the response of non-small cell lung cancer (NSCLC) to anticancer treatments. Methods: The characteristics, epidermal growth factor receptor (EGFR) mutation status, and clinical response to EGFR-TKIs treatment of enrolled patients were recorded. The viability of the spheroids generated from MPE of enrolled patients were evaluated by visualization of the formazan product of the MTT assay. Results: Spheroids were generated from 14 patients with NSCLC-related MPE. Patients with EGFR L861Q, L858R, or Exon 19 deletion all received EGFR-TKIs, and five of these seven patients responded to treatment. The viability of the spheroids generated from MPE of these five patients who responded to EGFR-TKIs treatment was significantly reduced after gefitinib treatment. On the other hand, gefitinib treatment did not reduce the viability of the spheroids generated from MPE of patients with EGFR wild type, Exon 20 insertion, or patients with sensitive EGFR mutation but did not respond to EGFR-TKIs treatment. Conclusion: Multicellular spheroids generated from NSCLC-related MPE might be used to predict the response of NSCLC to treatment. Full article
(This article belongs to the Special Issue Advances in Cell-Based Technologies for Precision Diagnostics)
Show Figures

Figure 1

12 pages, 1267 KiB  
Article
Integrating Routine Hematological and Extended Inflammatory Parameters as a Novel Approach for Timely Diagnosis and Prognosis in Sepsis Management
by Sianny Herawati, I Ketut Agus Somia, Sully Kosasih, I Nyoman Wande, Jethro Felim and I Made Dwi Payana
Diagnostics 2024, 14(9), 956; https://doi.org/10.3390/diagnostics14090956 - 2 May 2024
Viewed by 1962
Abstract
Sepsis is one of the major causes of morbidity and mortality in hospitals, especially in low- and middle-income countries, and represents a challenge to health care providers to carry out early detection, and accurate diagnosis and prognosis with cost-effective diagnostic tools. An observational [...] Read more.
Sepsis is one of the major causes of morbidity and mortality in hospitals, especially in low- and middle-income countries, and represents a challenge to health care providers to carry out early detection, and accurate diagnosis and prognosis with cost-effective diagnostic tools. An observational prospective study was conducted from December 2021 to December 2022 to investigate the extended inflammatory parameters (EIPs) for sepsis management and analyze the survival of septic patients in the emergency unit, intensive care unit (ICU) and inpatient ward. Patients suspected of having sepsis underwent a sequential organ failure assessment (SOFA) evaluation and had blood drawn for complete blood counts (CBCs). Significant changes were observed in various CBC parameters and EIPs, and the sepsis group was followed up with for 30-day mortality. The study highlighted a significant difference yet strong discriminatory power to differentiate sepsis with an AUC of 0.924 against the non-sepsis group and an AUC of 0.991 against the healthy control group using combination of white blood cells and EIPs. Furthermore, the study showed good predictive ability for 30-day mortality with a hazard ratio of 2.311. In summary, this study provides evidence that the utilization of EIPs may be valuable in diagnosing and predicting patient outcomes, and thus will be beneficial for sepsis management in the hospital. Full article
(This article belongs to the Special Issue Advances in Cell-Based Technologies for Precision Diagnostics)
Show Figures

Figure 1

15 pages, 2643 KiB  
Article
Hypermethylation Loci of ZNF671, IRF8, and OTX1 as Potential Urine-Based Predictive Biomarkers for Bladder Cancer
by Yuan-Hong Jiang, Yu-Shu Liu, Yu-Chung Wei, Jia-Fong Jhang, Hann-Chorng Kuo, Hsin-Hui Huang, Michael W. Y. Chan, Guan-Ling Lin, Wen-Chi Cheng, Shu-Chuan Lin and Hung-Jung Wang
Diagnostics 2024, 14(5), 468; https://doi.org/10.3390/diagnostics14050468 - 21 Feb 2024
Cited by 1 | Viewed by 1579
Abstract
Bladder cancer (BCa) is a significant health issue and poses a healthcare burden on patients, highlighting the importance of an effective detection method. Here, we developed a urine DNA methylation diagnostic panel for distinguishing between BCa and non-BCa. In the discovery stage, an [...] Read more.
Bladder cancer (BCa) is a significant health issue and poses a healthcare burden on patients, highlighting the importance of an effective detection method. Here, we developed a urine DNA methylation diagnostic panel for distinguishing between BCa and non-BCa. In the discovery stage, an analysis of the TCGA database was conducted to identify BCa-specific DNA hypermethylation markers. In the validation phase, DNA methylation levels of urine samples were measured with real-time quantitative methylation-specific PCR (qMSP). Comparative analysis of the methylation levels between BCa and non-BCa, along with the receiver operating characteristic (ROC) analyses with machine learning algorithms (logistic regression and decision tree methods) were conducted to develop practical diagnostic panels. The performance evaluation of the panel shows that the individual biomarkers of ZNF671, OTX1, and IRF8 achieved AUCs of 0.86, 0.82, and 0.81, respectively, while the combined yielded an AUC of 0.91. The diagnostic panel using the decision tree algorithm attained an accuracy, sensitivity, and specificity of 82.6%, 75.0%, and 90.9%, respectively. Our results show that the urine-based DNA methylation diagnostic panel provides a sensitive and specific method for detecting and stratifying BCa, showing promise as a standard test that could enhance the diagnosis and prognosis of BCa in clinical settings. Full article
(This article belongs to the Special Issue Advances in Cell-Based Technologies for Precision Diagnostics)
Show Figures

Figure 1

Back to TopTop